Rex Energy Reports Second Quarter 2017 Financial and Operational Results
Aug 08, 2017 20:02 pm UTC| Business
New BP Energy Company marketing arrangement enhances C3+ pricing structure and stabilizes cash flows on a quarter-to-quarter basisNew marketing arrangement allows Rex to reduce outstanding letters of credit by $14.1...
Aug 08, 2017 20:02 pm UTC| Business
- Interim results demonstrate ability of ACH-4471 to reduce LDH and improve hemoglobin and fatigue scores in patients with untreated PNH - - Global program expansion planned in PNH, C3G and IC-MPGN - - Conference call...
Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results
Aug 08, 2017 20:02 pm UTC| Business
Top-Line Results of First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Expected in Third Quarter 2017 Second Phase 3 Clinical Trial in Dravet Syndrome, Study 1504, Enrolling According to Plan Orphan Drug...
HTG Molecular Diagnostics Reports Second Quarter 2017 Results
Aug 08, 2017 20:02 pm UTC| Business
TUCSON, Ariz., Aug. 08, 2017 -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a provider of instruments, reagents and services for molecular profiling applications, today reported financial results for the three...
Foamix Reports Second Quarter 2017 Financial Results and Provides Business Update
Aug 08, 2017 20:01 pm UTC| Business
REHOVOT, Israel, Aug. 08, 2017 -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing...
Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results
Aug 08, 2017 20:01 pm UTC| Business
EMERYVILLE, Calif., Aug. 08, 2017 -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the second quarter ended June 30, 2017. “This is a very exciting time for...
Adverum Biotechnologies Reports Second Quarter 2017 Financial Results and Provides Update
Aug 08, 2017 20:01 pm UTC| Business
MENLO PARK, Calif., Aug. 08, 2017 -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a leading gene therapy company advancing novel medicines that have the potential to address unmet needs in serious rare and ocular...